Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Total Non-Current Liabilities (2016 - 2026)

Eledon Pharmaceuticals filings provide 3 years of Total Non-Current Liabilities readings, the most recent being $1.4 million for Q4 2017.

  • On a quarterly basis, Total Non-Current Liabilities rose 1614.29% to $1.4 million in Q4 2017 year-over-year; TTM through Dec 2017 was $1.4 million, a 1614.29% increase, with the full-year FY2017 number at $1.4 million, up 1614.29% from a year prior.
  • Total Non-Current Liabilities hit $1.4 million in Q4 2017 for Eledon Pharmaceuticals, up from $94000.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $6.2 million in Q1 2016 to a low of $48000.0 in Q1 2017.
  • Median Total Non-Current Liabilities over the past 3 years was $156000.0 (2016), compared with a mean of $1.7 million.
  • The widest YoY moves for Total Non-Current Liabilities: up 1614.29% in 2017, down 99.22% in 2017.
  • Eledon Pharmaceuticals' Total Non-Current Liabilities stood at $88000.0 in 2015, then dropped by 4.55% to $84000.0 in 2016, then surged by 1614.29% to $1.4 million in 2017.
  • The last three reported values for Total Non-Current Liabilities were $1.4 million (Q4 2017), $94000.0 (Q3 2017), and $245000.0 (Q2 2017) per Business Quant data.